Novartis has announced promising late-stage results for GanLum, a malaria treatment that contains a novel molecule called ganaplacide. Experts note the molecule’s novelty: it acts in a way unlike existing antimalarials, so the Plasmodium parasite has no prior exposure and therefore no established defence. Drug-resistant malaria, first observed in Cambodia in 2008 and more recently reported in countries such as Rwanda, Uganda and Tanzania, has made new options urgent.
The trial enrolled over 1,600 patients across 12 countries in sub‑Saharan Africa. GanLum was given as a sachet of granules once a day for three days and cured 97.4% of participants, compared with 94% for an existing treatment. In addition to treating symptoms, the drug targets the parasite as it prepares to transmit to mosquitoes, a step that could reduce new infections and limit the spread of resistance.
Medicines for Malaria Venture developed the compound with Novartis and said regulatory approvals could come in around 16 months, with possible market availability in 2027. The compound was identified after a screening of 2.3 million molecules at Novartis labs in San Diego, done in collaboration with the Swiss Tropical and Public Health Institute, Wellcome Trust and Medicines for Malaria Venture. Trial data were presented at the American Society of Tropical Medicine and Hygiene meeting in Toronto, and several researchers described the results as an important advance.
Difficult words
- novel — new and different from what exists
- parasite — organism that lives in another organism
- resistance — ability of organisms to survive treatment
- sachet — small sealed packet for a single dose
- transmit — to pass disease or organism to another
- screening — testing many items to find useful ones
- compound — a substance made of two or more parts
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- How could a drug that reduces parasite transmission to mosquitoes affect efforts to stop malaria?
- What challenges might slow access to GanLum even after regulatory approval?
- Why is finding a molecule with no prior exposure to the parasite important for fighting drug resistance?
Related articles
Ancestral healing in the Caribbean
Ancestral healing asks societies to face historical wounds so people can live healthier lives. In the Caribbean, educators combine shamanic practices, nervous-system work and cultural rituals with scientific findings about trauma and community care.
Few new antibiotics for children amid rising resistance
Global experts warn that few child-friendly antibiotics are being developed while antimicrobial resistance already causes millions of deaths. A 2026 Benchmark finds fewer drugs in company pipelines and a shortage of medicines for under-five children.
Blocking a key immune signal may prolong post-surgery pain
A study led by Geoffroy Laumet found that blocking the immune molecule TNF-α after surgery in mice made pain last longer. The authors warn this does not mean stopping all anti-inflammatory treatment and call for targeted approaches.
